셀젠
셀젠텍 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 김회율, was filed 16 Oct 2023.
셀젠텍: what insiders have been doing
셀젠텍, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). The past year has been quiet: not a single insider filing for 셀젠텍. The previous disclosure was published on 14 November 2023.
In the same sector, recent insider purchases at Relmada Therapeutics, Inc. and MAIA Biotechnology, Inc. also feature in our signals. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Insider Decl.
32
Thresholds
n/a
Buy Volume
n/a
11 ops. · all time
Sell Volume
n/a
5 ops. · all time
Financial data
· cache
Last declaration on 14 November 2023
Declarations32 total
- 164,765 sharesKRXDART:20231114001447
- 166,835 sharesKRXDART:20231016000235
- 5,445 sharesShareKRXDART:20231016000143Canonical exit: 22 Mar 2023 (T+90)
- 4,406 sharesShareKRXDART:20230831001553Canonical exit: 27 Nov 2023 (T+90)
- 183,638 sharesKRXDART:20230816000224
- 250,417 sharesKRXDART:20230816000214
- 250,417 sharesKRXDART:20230706000375
- 1,165 sharesShareKRXDART:20221214000190Canonical exit: 9 Mar 2023 (T+90)
- 2,023 sharesKRXDART:20221114002473Canonical exit: 12 Feb 2023 (T+90)
- 1,050 sharesShareKRXDART:20220929000264Canonical exit: 26 Dec 2022 (T+90)
- 1,679 sharesShareKRXDART:20220922000084Canonical exit: 19 Dec 2022 (T+90)
- 2,200 sharesShareKRXDART:20220916000132Canonical exit: 13 Dec 2022 (T+90)
- 2,900 sharesKRXDART:20220916000134Canonical exit: 15 Dec 2022 (T+90)
- 1,581 sharesKRXDART:20220621000180Canonical exit: 19 Sept 2022 (T+90)
- 2,000 sharesKRXDART:20220407001303Canonical exit: 6 Jul 2022 (T+90)
- 1,093 sharesKRXDART:20220317000211Canonical exit: 15 Jun 2022 (T+90)
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
25 of 32 declarations
About 셀젠텍
셀젠텍 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative therapeutic solutions.
